Trial reportInternational urogynecology journal and pelvic floor dysfunction2007
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
Trial report in International urogynecology journal and pelvic floor dysfunction, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?International urogynecology journal · 2021Pooled it
- Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.Journal of Korean medical science · 2017Trial
- Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.World journal of urology · 2015Trial
- Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.The Journal of urology · 2013Trial
- Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy.International urogynecology journal and pelvic floor dysfunction · 2008Trial
- Assessment of the Most Impactful Combination of Factors Associated with Nocturia and to Define Nocturnal Polyuria by Multivariate Modelling.Journal of clinical medicine · 2020Article
- Management Strategies for Nocturia.Current urology reports · 2019Review
- Development of a multivariate prediction model for nocturia, based on urinary tract etiologies.International journal of clinical practice · 2019Observational
- Nocturia: The circadian voiding disorder.Investigative and clinical urology · 2016Review
- Management of nocturia in the female.Current urology reports · 2015Review
- Medication adherence in the management of nocturia: challenges and solutions.Patient preference and adherence · 2015Review
- Combination therapies for the management of nocturia and its comorbidities.Research and reports in urology · 2015Review
- Current evaluation and treatment of nocturia.Korean journal of urology · 2013Article
- Comparison of diary-derived bladder and sleep measurements across OAB individuals, primary insomniacs, and healthy controls.International urogynecology journal · 2013Article
- The dilemma of nocturia.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2012Article
- Nocturia: focus on etiology and consequences.Reviews in urology · 2012Article
- A systematic evaluation of factors associated with nocturia--the population-based FINNO study.American journal of epidemiology · 2009Article
- Clinical pharmacokinetics and pharmacodynamics of solifenacin.Clinical pharmacokinetics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objectives of this study are to determine whether patients with overactive bladder (OAB) and nocturia achieved relief of their nighttime voiding symptoms when treated with solifenacin and whether having nocturnal polyuria (NP) affected that response. The patients pooled from four phase III clinical trials were evaluated for reductions in nocturia episodes after treatment with solifenacin (5 or 10 mg) or placebo. A second analysis was performed in patients with and without NP. The patients treated with solifenacin experienced statistically significant reductions in nocturia episodes; median reductions were -35.5% for 5 mg of solifenacin and -36.4% for 10 mg of solifenacin compared with -25.0% for placebo, and significantly more patients treated with solifenacin vs placebo achieved a mean nocturic frequency of <or=1 episode/night. Solifenacin significantly reduced nocturia episodes only in patients without NP (mean change was -0.61 episodes/night for both doses compared with -0.43 episodes for placebo). Solifenacin significantly improved nocturia symptoms only in OAB patients without NP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.